<DOC>
	<DOCNO>NCT00083122</DOCNO>
	<brief_summary>This phase II trial study well give cisplatin together flavopiridol work treat patient advanced ovarian epithelial cancer primary peritoneal cancer . Drugs use chemotherapy , cisplatin flavopiridol , work different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell .</brief_summary>
	<brief_title>Cisplatin Flavopiridol Treating Patients With Advanced Ovarian Epithelial Cancer Primary Peritoneal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine response rate , time progression , survival patient advance ovarian epithelial primary peritoneal cancer treat cisplatin flavopiridol . II . Determine toxicity regimen patient . OUTLINE : This multicenter study . Patients accrue two separate group ( Group 2 close accrual 3/10/06 ) . GROUP 1 : Patients receive cisplatin IV 30 minute flavopiridol IV 24 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . GROUP 2 ( Closed accrual 3/10/06 ) : Patients receive cisplatin IV 30 minute flavopiridol IV 24 hour day 1 . Courses repeat every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 3 year .</detailed_description>
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Alvocidib</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>Histologically confirm ovarian epithelial primary peritoneal cancer : Advanced disease Meets least 1 follow criterion : Measurable disease ; Evaluable disease plus CA 125 &gt; = 2 time posttreatment nadir Treated 1 , 1 , prior platincontaining chemotherapy regimen ( e.g. , paclitaxel carboplatinbased ) ovarian epithelial primary peritoneal cancer Prior treatment regimen first relapse allow ; No 3 total chemotherapy regimen allow provide exactly 1 platincontaining ; Must also platinresistant disease define Group 1 ; Rechallenge single regimen upon progression hiatus therapy count single regimen Group 1 , meet 1 follow criterion : Patients relapse &lt; 6 month completion postdebulking chemotherapy ; `` Platinum sensitive '' patient second relapse treated/rechallenged initial regimen upon first relapse Group 2 ( Closed accrual 3/10/06 ) : Patients relapse &gt; = 6 month completion postdebulking chemotherapy retreat different regimen No CNS metastases Performance status : ECOG 02 Hematopoietic : Absolute neutrophil count &gt; = 1,500/mm3 ; Platelet count &gt; = 100,000/mm3 ; Hemoglobin &gt; = 10 g/dL ( Note : May support transfusion , epoetin alfa , darbepoetin alfa ) Hepatic : AST = &lt; 2.5 time upper limit normal ( ULN ) ; Alkaline phosphatase = &lt; 2.5 time ULN ; Bilirubin = &lt; 1.5 time ULN Renal : Creatinine = &lt; 1.5 time ULN Cardiovascular : No cardiac arrhythmia ; No cardiac failure Not pregnant nursing Negative pregnancy test More 3 week since prior chemotherapy ( 6 week nitrosoureas ) More 3 week since prior radiotherapy Recovered prior therapy Fertile patient must use effective contraception No malignancy within past 5 year except nonmelanoma skin cancer carcinoma situ cervix No diabetes No peripheral neuropathy &gt; = grade 2 No baseline diarrhea ( &gt; = 4 stools/day ) No uncontrolled infection No concurrent uncontrolled serious medical condition No concurrent routine colonystimulating factor</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
</DOC>